Ravi Kalhan, MD, MS
Disclosures: Consulting Fee-Ended 5/31/2018-GlaxoSmithKline|Consulting Fee-Ended - April 2018-CVS Caremark|Consulting Fee-Ended - January 2018-Boston Scientific Corporation|Research Grant Support (to NU)-Ended - March 2018-GlaxoSmithKline|Research Grant Support (to NU)-Current-BTG/PneumRx|Research Grant Support (to NU)-Current-Spiration
No Bio Available.